Northern Trust Corp boosted its stake in shares of Glaukos Corporation (NYSE:GKOS) by 15.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 251,342 shares of the medical instruments supplier’s stock after acquiring an additional 33,017 shares during the quarter. Northern Trust Corp owned about 0.73% of Glaukos Corporation worth $10,424,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently bought and sold shares of the business. American International Group Inc. increased its stake in Glaukos Corporation by 7.1% in the 1st quarter. American International Group Inc. now owns 10,293 shares of the medical instruments supplier’s stock valued at $528,000 after purchasing an additional 681 shares in the last quarter. PNC Financial Services Group Inc. increased its position in Glaukos Corporation by 1.4% during the second quarter. PNC Financial Services Group Inc. now owns 70,313 shares of the medical instruments supplier’s stock worth $2,915,000 after buying an additional 994 shares in the last quarter. GSA Capital Partners LLP increased its position in Glaukos Corporation by 3.7% during the second quarter. GSA Capital Partners LLP now owns 35,080 shares of the medical instruments supplier’s stock worth $1,455,000 after buying an additional 1,237 shares in the last quarter. Teachers Advisors LLC grew its position in shares of Glaukos Corporation by 6.2% in the first quarter. Teachers Advisors LLC now owns 29,512 shares of the medical instruments supplier’s stock valued at $1,514,000 after purchasing an additional 1,723 shares during the period. Finally, BNP Paribas Arbitrage SA grew its position in shares of Glaukos Corporation by 740.6% in the second quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock valued at $147,000 after purchasing an additional 3,118 shares during the period. 93.07% of the stock is owned by institutional investors.
A number of research analysts recently weighed in on the company. BidaskClub upgraded Glaukos Corporation from a “hold” rating to a “buy” rating in a report on Tuesday, September 12th. Cantor Fitzgerald reiterated a “buy” rating and issued a $60.00 price target (up previously from $54.00) on shares of Glaukos Corporation in a research note on Thursday, September 14th. Piper Jaffray Companies reissued a “buy” rating and issued a $56.00 price objective on shares of Glaukos Corporation in a report on Thursday, August 3rd. Roth Capital lowered their price objective on Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating for the company in a report on Thursday, August 3rd. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $54.00 target price on shares of Glaukos Corporation in a report on Friday, September 1st. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $46.57.
COPYRIGHT VIOLATION NOTICE: “Glaukos Corporation (NYSE:GKOS) Shares Bought by Northern Trust Corp” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/11/23/northern-trust-corp-increases-stake-in-glaukos-corporation-gkos.html.
In other news, CEO Thomas William Burns sold 73,788 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $41.36, for a total transaction of $3,051,871.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Orbimed Advisors Llc sold 580,200 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $38.73, for a total transaction of $22,471,146.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 655,200 shares of company stock valued at $25,573,013. 16.40% of the stock is owned by corporate insiders.
Glaukos Corporation (NYSE GKOS) traded down $0.85 during midday trading on Wednesday, hitting $24.50. 1,916,199 shares of the stock were exchanged, compared to its average volume of 640,727. The firm has a market capitalization of $846.85 and a P/E ratio of 235.08. Glaukos Corporation has a 1-year low of $23.44 and a 1-year high of $52.49.
Glaukos Corporation (NYSE:GKOS) last released its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.06. Glaukos Corporation had a negative net margin of 0.64% and a positive return on equity of 3.50%. The company had revenue of $40.41 million during the quarter, compared to analysts’ expectations of $38.69 million. During the same period in the prior year, the company earned $0.03 earnings per share. The business’s quarterly revenue was up 36.6% compared to the same quarter last year. equities analysts expect that Glaukos Corporation will post -0.03 EPS for the current fiscal year.
Glaukos Corporation Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.